Risk factors in the development of stem cell therapy |
| |
Authors: | Carla A Herberts Marcel SG Kwa Harm PH Hermsen |
| |
Affiliation: | (1) Centre for Biological Medicines and Medical Technology, National Institute for Public Health and the Environment, A. v. Leeuwenhoeklaan 9, P.O.Box 1, 3720 BA Bilthoven, The Netherlands;(2) Department of Pharmacovigilance, Netherlands Medicines Evaluation Board, Kalvermarkt 53, 2511 CB Den Haag, The Netherlands |
| |
Abstract: | Stem cell therapy holds the promise to treat degenerative diseases, cancer and repair of damaged tissues for which there are currently no or limited therapeutic options. The potential of stem cell therapies has long been recognised and the creation of induced pluripotent stem cells (iPSC) has boosted the stem cell field leading to increasing development and scientific knowledge. Despite the clinical potential of stem cell based medicinal products there are also potential and unanticipated risks. These risks deserve a thorough discussion within the perspective of current scientific knowledge and experience. Evaluation of potential risks should be a prerequisite step before clinical use of stem cell based medicinal products. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|